Title:Benzothiazoles - Scaffold of Interest for CNS Targeted Drugs
Volume: 22
Issue: 6
Author(s): Lukas Hroch, Laura Aitken, Ondrej Benek, Martin Dolezal, Kamil Kuca, Frank Gunn-Moore and Kamil Musilek
Affiliation:
Keywords:
Alzheimer disease, amyloid-beta, amyotrophic lateral sclerosis, anticonvulsant, benzothiazole, neuroprotection.
Abstract: Benzothiazole compounds represent heterocyclic systems comprising a benzene ring fused with a thiazole ring
containing nitrogen and sulphur in its structure. Besides the presence of a benzothiazole core in naturally occurring molecules,
synthesized compounds containing a benzothiazole moiety in their structure proved to be a significant class of potential
therapeutics, as they exhibit biological effects such as antitumor, antibacterial, antitubercular, antiviral, anthelmintic,
antidiabetic and many others. Apart from the aforementioned peripheral or microbial active sites, benzothiazole analogues
are also biologically active compounds in the central nervous system, where some approved drugs containing a
benzothiazole moiety have already been identified and are used in the treatment of various neurological disorders. New
benzothiazole molecules are currently under development and are being evaluated for several uses including diagnostics
and as therapeutic drug candidates for the treatment of epilepsy and neurodegenerative diseases such as Alzheimer’s disease,
Huntington’s disease and amyotrophic lateral sclerosis amongst others.
